Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study
Context: Currently, there is no effective antiviral therapy recommended for novel coronavirus pneumonia 2019 (COVID-19). Aims: To assess the safety of ozonized saline solution (O3SS) used as a complementary therapy in adult COVID-19 patients. Methods: Twenty-five adult patients hospitalized with mild to severe symptoms of COVID-19, who met the inclusion criteria and were treated from April 18 to April 26, 2020, at Virgen De La Paloma Hospital, Madrid, Spain were included in this study. Patients were assigned to receive standard care consisting ceftriaxone (250 mg – 2 g twice daily for 7 days) plus azithromycin (500 mg once daily for 5 days), of 200 – 400 mg hydroxychloroquine twice daily for 5-7 days plus tocilizumab 400 mg twice daily for 5 days, low molecular weight heparin and 40 to 60 mg metil-prednisone plus O3SS, 200 mL, 3-5 µg/mL per day for 10 days. No control group was included, the data was compared to clinical trials in this subject. Secondary endpoints assessed included the clinical status of participants, laboratory examinations, and duration of viral shedding. Results: Patients with COVID-19 with mild to severe symptoms who received intravenous O3SS as an adjunct treatment experienced no side effects. The main results of O3SS treatment were a tendency to improve clinical symptoms without side effects. None of the patients treated died. Conclusions: Early evidence of efficacy shown improvements in symptoms such as dyspnea, weakness, and reduction in body temperature were observed and corresponded to improvements in laboratory results including D-dimer, fibrinogen, lactate dehydrogenase, and C-reactive protein. These preliminary data will serve as the basis for a future study of the effectiveness of this therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of Pharmacy & Pharmacognosy Research - 9(2021), 2, Seite 126-142 |
| Sprache: |
Englisch ; Spanisch |
|---|
| Beteiligte Personen: |
Adriana Schwartz [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ026199351 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ026199351 | ||
| 003 | DE-627 | ||
| 005 | 20230307095837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ026199351 | ||
| 035 | |a (DE-599)DOAJf9d8a49cdcbf4424a4a97e8ecc693726 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Adriana Schwartz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complementary application of the ozonized saline solution in mild and severe patients with pneumonia COVID-19: A non-randomized pilot study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Context: Currently, there is no effective antiviral therapy recommended for novel coronavirus pneumonia 2019 (COVID-19). Aims: To assess the safety of ozonized saline solution (O3SS) used as a complementary therapy in adult COVID-19 patients. Methods: Twenty-five adult patients hospitalized with mild to severe symptoms of COVID-19, who met the inclusion criteria and were treated from April 18 to April 26, 2020, at Virgen De La Paloma Hospital, Madrid, Spain were included in this study. Patients were assigned to receive standard care consisting ceftriaxone (250 mg – 2 g twice daily for 7 days) plus azithromycin (500 mg once daily for 5 days), of 200 – 400 mg hydroxychloroquine twice daily for 5-7 days plus tocilizumab 400 mg twice daily for 5 days, low molecular weight heparin and 40 to 60 mg metil-prednisone plus O3SS, 200 mL, 3-5 µg/mL per day for 10 days. No control group was included, the data was compared to clinical trials in this subject. Secondary endpoints assessed included the clinical status of participants, laboratory examinations, and duration of viral shedding. Results: Patients with COVID-19 with mild to severe symptoms who received intravenous O3SS as an adjunct treatment experienced no side effects. The main results of O3SS treatment were a tendency to improve clinical symptoms without side effects. None of the patients treated died. Conclusions: Early evidence of efficacy shown improvements in symptoms such as dyspnea, weakness, and reduction in body temperature were observed and corresponded to improvements in laboratory results including D-dimer, fibrinogen, lactate dehydrogenase, and C-reactive protein. These preliminary data will serve as the basis for a future study of the effectiveness of this therapy. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a ozone therapy | |
| 650 | 4 | |a ozonized saline solution | |
| 650 | 4 | |a pneumonia | |
| 650 | 4 | |a sars-cov-2 | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Gregorio Martínez-Sánchez |e verfasserin |4 aut | |
| 700 | 0 | |a Alejandra M. de Lucía |e verfasserin |4 aut | |
| 700 | 0 | |a Sergio M. Viana |e verfasserin |4 aut | |
| 700 | 0 | |a Alina M. Constanta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Pharmacy & Pharmacognosy Research |d GarVal Editorial Ltda., 2015 |g 9(2021), 2, Seite 126-142 |w (DE-627)DOAJ000016683 |x 07194250 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:2 |g pages:126-142 |
| 856 | 4 | 0 | |u https://doaj.org/article/f9d8a49cdcbf4424a4a97e8ecc693726 |z kostenfrei |
| 856 | 4 | 0 | |u https://jppres.com/jppres/pdf/vol9/jppres20.971_9.2.126.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0719-4250 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 2 |h 126-142 | ||